| # | Title | Journal | Year | Citations |
|---|
| 1 | Flow cytometric immunophenotyping for hematologic neoplasms | Blood | 2008 | 527 |
| 2 | Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results Database | Journal of Clinical Oncology | 2007 | 488 |
| 3 | Critical role of the extracellular signal–regulated kinase–MAPK pathway in osteoblast differentiation and skeletal development | Journal of Cell Biology | 2007 | 460 |
| 4 | Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma | Blood | 2007 | 413 |
| 5 | Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial | Lancet Oncology, The | 2016 | 352 |
| 6 | Upper-Extremity Transplantation Using a Cell-Based Protocol to Minimize Immunosuppression | Annals of Surgery | 2013 | 184 |
| 7 | Treatment of Stage IV Non-small Cell Lung Cancer | Chest | 2013 | 180 |
| 8 | Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells | Journal of Cellular Biochemistry | 2008 | 167 |
| 9 | Hearing Loss, Quality of Life, and Academic Problems in Long-term Neuroblastoma Survivors: A Report From the Children's Oncology Group | Pediatrics | 2007 | 158 |
| 10 | Mesenchymal stem cell secretome and regenerative therapy after cancer | Biochimie | 2013 | 150 |
| 11 | Evaluating the supportive care costs of severe radiochemotherapy‐induced mucositis and pharyngitis | Cancer | 2008 | 147 |
| 12 | The Role of the Estrogen Pathway in the Tumor Microenvironment | International Journal of Molecular Sciences | 2018 | 145 |
| 13 | Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma | International Journal of Molecular Sciences | 2018 | 141 |
| 14 | Adolescent and young adult oncology—past, present, and future | Ca-A Cancer Journal for Clinicians | 2019 | 137 |
| 15 | Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era | ACS Nano | 2021 | 134 |
| 16 | Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck | Annals of Oncology | 2013 | 127 |
| 17 | Pulmonary Embolism Incidence Is Increasing with Use of Spiral Computed Tomography | American Journal of Medicine | 2008 | 119 |
| 18 | Microvasculature-on-a-chip for the long-term study of endothelial barrier dysfunction and microvascular obstruction in disease | Nature Biomedical Engineering | 2018 | 118 |
| 19 | CD4CD8αα Lymphocytes, A Novel Human Regulatory T Cell Subset Induced by Colonic Bacteria and Deficient in Patients with Inflammatory Bowel Disease | PLoS Biology | 2014 | 117 |
| 20 | Sensitive liquid chromatography–mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma | Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences | 2003 | 116 |
| 21 | Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study | Blood | 2012 | 111 |
| 22 | Modulation of Signal Transducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFNα2b | Clinical Cancer Research | 2007 | 110 |
| 23 | The NSABP Study of Tamoxifen and Raloxifene (STAR) trial | Expert Review of Anticancer Therapy | 2009 | 103 |
| 24 | Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial | European Journal of Cancer | 2018 | 100 |
| 25 | A phase 2, randomized study of SB‐485232, rhIL‐18, in patients with previously untreated metastatic melanoma | Cancer | 2009 | 96 |
| 26 | Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States | Blood | 2016 | 96 |
| 27 | Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma | Clinical Cancer Research | 2006 | 94 |
| 28 | Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia | Leukemia | 2009 | 91 |
| 29 | IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma | Clinical Cancer Research | 2020 | 88 |
| 30 | Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease | Blood | 2011 | 86 |
| 31 | Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients | Cancer Immunology Research | 2017 | 84 |
| 32 | Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy–Mediated Metastatic Melanoma Phenotype | Cancer Discovery | 2015 | 82 |
| 33 | A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma | Oral Oncology | 2013 | 81 |
| 34 | SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma | Cancer | 2016 | 80 |
| 35 | Mesenchymal Stem Cells in the Tumor Microenvironment | Advances in Experimental Medicine and Biology | 2020 | 79 |
| 36 | You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia | Leukemia | 2015 | 77 |
| 37 | Targeting the Phosphatidylinositol 3-Kinase Pathway in Multiple Myeloma | Clinical Cancer Research | 2007 | 71 |
| 38 | Lack of de novo phosphatidylinositol synthesis leads to endoplasmic reticulum stress and hepatic steatosis in cdipt-deficient zebrafish | Hepatology | 2011 | 71 |
| 39 | Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: New trends and future opportunities | Surgery | 2013 | 71 |
| 40 | Risk factors for inhibitor formation in haemophilia: a prevalent case–control study | Haemophilia | 2009 | 69 |
| 41 | Plasma thrombospondin‐1 is increased during acute sickle cell vaso‐occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates | American Journal of Hematology | 2012 | 68 |
| 42 | Hierarchy of α Fetoprotein (AFP)-Specific T Cell Responses in Subjects with AFP-Positive Hepatocellular Cancer | Journal of Immunology | 2006 | 67 |
| 43 | Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations | Cancers | 2020 | 65 |
| 44 | Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer | Annals of Oncology | 2016 | 64 |
| 45 | Coronary atherosclerosis and cardiovascular mortality in hemophilia | Journal of Thrombosis and Haemostasis | 2010 | 63 |
| 46 | Localization of CD44 and CD90 positive cells to the invasive front of breast tumors | Cytometry Part B - Clinical Cytometry | 2010 | 59 |
| 47 | Effect of a proton pump inhibitor on the pharmacokinetics of imatinib | British Journal of Clinical Pharmacology | 2009 | 58 |
| 48 | DAF-12 Regulates a Connected Network of Genes to Ensure Robust Developmental Decisions | PLoS Genetics | 2011 | 57 |
| 49 | An Update on Adjuvant Interferon for Melanoma | Cancer Control | 2002 | 56 |
| 50 | Gene therapy in hemophilia A: a cost-effectiveness analysis | Blood Advances | 2018 | 56 |
